OCZ103-OS + platinum + gemcitabine

OCZ103-OS + platinum + gemcitabine is a three-drug combination investigational regimen studied primarily in first-line treatment for stage IV non-small cell lung cancer. **OCZ103-OS** is an experimental agent whose exact molecular nature is not publicly disclosed in the clinical trial registries, but it is being investigated as an additive to standard platinum-based (such as cisplatin or carboplatin) and gemcitabine chemotherapy doublets[1][5]. Platinum agents act by forming DNA adducts to induce apoptosis in cancer cells, while gemcitabine inhibits DNA synthesis by acting as a nucleoside analogue and ribonucleotide reductase inhibitor[3][7]. OCZ103-OS is likely intended to potentiate or synergize with the cytotoxic effects of this doublet, though its primary mechanism and structure remain undisclosed in available sources.